<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29717222</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>May</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic limbic encephalitis associated with lung cancer.</ArticleTitle>
        <Pagination>
          <StartPage>6792</StartPage>
          <MedlinePgn>6792</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">6792</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-018-25294-y</ELocationID>
        <Abstract>
          <AbstractText>Paraneoplastic limbic encephalitis (PLE) is a rare autoimmune neurological syndrome observed in lung cancer patients. We retrospectively investigated the clinical characteristics, treatment responses, and prognoses in 16 PLE patients who were subsequently diagnosed with lung cancer. Fifteen patients initially presented with disturbance of consciousness, 13 with disorientation, and 12 with seizures. Thirteen patients had autoantibodies, including eight with gamma aminobutyric acid B receptor (GABA<sub>B</sub>R) antibodies and eight with Hu antibodies. PET-CT revealed lung neoplasms in 13 patients, nine of whom exhibited abnormal metabolic activity in the temporal lobe and hippocampus. Fifteen cases were confirmed as limited-stage small cell lung cancer and one as stage IV large cell neuroendocrine carcinoma. Eleven patients received immunomodulatory therapy, and four showed neurological improvement, who all had antibodies against GABA<sub>B</sub>R. Fifteen patients received chemotherapy, of which 14 maintained or improved their PLE status. The overall cancer response rate was 75%, and two-year overall survival was 74.7%. Our results suggest patients with GABA<sub>B</sub> encephalitis might respond better to immunotherapy than the classical PLE patients with anti-Hu antibodies. Anti-cancer treatment could further improve neurological symptoms. Lung cancer patients with PLE, especially those in limited stage, might have better outcome due to earlier diagnosis and prompt anti-cancer treatment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Kaini</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guan</LastName>
            <ForeName>Hongzhi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Minjiang</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Longyun</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Mengzhao</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China. mengzhaowang@sina.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>05</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051959">ELAV Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018080">Receptors, GABA-B</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003221" MajorTopicYN="N">Confusion</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051959" MajorTopicYN="N">ELAV Proteins</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020363" MajorTopicYN="N">Limbic Encephalitis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018080" MajorTopicYN="N">Receptors, GABA-B</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055752" MajorTopicYN="N">Small Cell Lung Carcinoma</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29717222</ArticleId>
        <ArticleId IdType="pmc">PMC5931551</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-018-25294-y</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-018-25294-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Gultekin SH, et al.  Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain: a journal of neurology. 2000;123(Pt 7):1481–1494. doi: 10.1093/brain/123.7.1481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/123.7.1481</ArticleId>
            <ArticleId IdType="pubmed">10869059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, et al.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain: a journal of neurology. 2001;124:1138–1148. doi: 10.1093/brain/124.6.1138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/124.6.1138</ArticleId>
            <ArticleId IdType="pubmed">11353730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheid R, et al.  Neuropsychiatric findings in anti-Ma2-positive paraneoplastic limbic encephalitis. Neurology. 2003;61:1159–1161. doi: 10.1212/01.WNL.0000085873.45099.E2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000085873.45099.E2</ArticleId>
            <ArticleId IdType="pubmed">14581698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gozzard P, et al.  Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study. Neurology. 2015;85:235–239. doi: 10.1212/WNL.0000000000001721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000001721</ArticleId>
            <ArticleId IdType="pmc">PMC4516293</ArticleId>
            <ArticleId IdType="pubmed">26109714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. Journal of neurology. 2010;257:509–517. doi: 10.1007/s00415-009-5431-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-009-5431-9</ArticleId>
            <ArticleId IdType="pubmed">20035430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grisold W, Giometto B, Vitaliani R, Oberndorfer S. Current approaches to the treatment of paraneoplastic encephalitis. Therapeutic advances in neurological disorders. 2011;4:237–248. doi: 10.1177/1756285611405395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756285611405395</ArticleId>
            <ArticleId IdType="pmc">PMC3131173</ArticleId>
            <ArticleId IdType="pubmed">21765874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoftberger R, et al.  Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology. 2013;81:1500–1506. doi: 10.1212/WNL.0b013e3182a9585f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182a9585f</ArticleId>
            <ArticleId IdType="pmc">PMC3888170</ArticleId>
            <ArticleId IdType="pubmed">24068784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelley BP, et al.  Autoimmune Encephalitis: Pathophysiology and Imaging Review of an Overlooked Diagnosis. AJNR Am J Neuroradiol. 2017;38:1070–1078. doi: 10.3174/ajnr.A5086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3174/ajnr.A5086</ArticleId>
            <ArticleId IdType="pubmed">28183838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams TJ, et al.  Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. JAMA neurology. 2016;73:928–933. doi: 10.1001/jamaneurol.2016.1399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2016.1399</ArticleId>
            <ArticleId IdType="pubmed">27271951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fellner, A. et al. Neurologic complications of immune checkpoint inhibitors. Journal of neuro-oncology, 10.1007/s11060-018-2752-5 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29332184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. The Lancet. Neurology. 2002;1:294–305. doi: 10.1016/S1474-4422(02)00135-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(02)00135-7</ArticleId>
            <ArticleId IdType="pubmed">12849427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, et al.  A clinical approach to diagnosis of autoimmune encephalitis. The Lancet. Neurology. 2016;15:391–404. doi: 10.1016/S1474-4422(15)00401-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(15)00401-9</ArticleId>
            <ArticleId IdType="pmc">PMC5066574</ArticleId>
            <ArticleId IdType="pubmed">26906964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serafini A, et al.  Paraneoplastic epilepsy. Epilepsy Behav. 2016;61:51–58. doi: 10.1016/j.yebeh.2016.04.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yebeh.2016.04.046</ArticleId>
            <ArticleId IdType="pubmed">27304613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim TJ, et al.  Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis. Journal of neuroimmunology. 2014;270:45–50. doi: 10.1016/j.jneuroim.2014.02.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2014.02.011</ArticleId>
            <ArticleId IdType="pubmed">24662003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao S, et al.  Clinical Characteristics and Predictors of Outcome for Onconeural Antibody-Associated Disorders: A Retrospective Analysis. Front Neurol. 2017;8:584. doi: 10.3389/fneur.2017.00584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2017.00584</ArticleId>
            <ArticleId IdType="pmc">PMC5694024</ArticleId>
            <ArticleId IdType="pubmed">29180979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ulrich D, Bettler B. GABA(B) receptors: synaptic functions and mechanisms of diversity. Curr Opin Neurobiol. 2007;17:298–303. doi: 10.1016/j.conb.2007.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.conb.2007.04.001</ArticleId>
            <ArticleId IdType="pubmed">17433877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster E, et al.  Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. The Lancet. Neurology. 2010;9:67–76. doi: 10.1016/S1474-4422(09)70324-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(09)70324-2</ArticleId>
            <ArticleId IdType="pmc">PMC2824142</ArticleId>
            <ArticleId IdType="pubmed">19962348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. 2011;76:795–800. doi: 10.1212/WNL.0b013e31820e7b8d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e31820e7b8d</ArticleId>
            <ArticleId IdType="pmc">PMC3053332</ArticleId>
            <ArticleId IdType="pubmed">21357831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: a systematic review. Expert review of neurotherapeutics. 2015;15:1391–1419. doi: 10.1586/14737175.2015.1115720.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14737175.2015.1115720</ArticleId>
            <ArticleId IdType="pubmed">26559389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stinchcombe, T. E. Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer. The oncologist, 10.1634/theoncologist.2017-0204 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5728020</ArticleId>
            <ArticleId IdType="pubmed">28778960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glatzer, M. et al. Treatment of limited disease small cell lung cancer: the multidisciplinary team. The European respiratory journal50, 10.1183/13993003.00422-2017 (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>Kaira K, et al.  Small-cell lung cancer with voltage-gated calcium channel antibody-positive paraneoplastic limbic encephalitis: a case report. Journal of medical case reports. 2014;8:119. doi: 10.1186/1752-1947-8-119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1752-1947-8-119</ArticleId>
            <ArticleId IdType="pmc">PMC4000153</ArticleId>
            <ArticleId IdType="pubmed">24712889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuliani L, et al.  Paraneoplastic limbic encephalitis associated with potassium channel antibodies: value of anti-glial nuclear antibodies in identifying the tumour. Journal of neurology, neurosurgery, and psychiatry. 2007;78:204–205. doi: 10.1136/jnnp.2006.102467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2006.102467</ArticleId>
            <ArticleId IdType="pmc">PMC2077643</ArticleId>
            <ArticleId IdType="pubmed">17229755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bak TH, Antoun N, Balan KK, Hodges JR. Memory lost, memory regained: neuropsychological findings and neuroimaging in two cases of paraneoplastic limbic encephalitis with radically different outcomes. Journal of neurology, neurosurgery, and psychiatry. 2001;71:40–47. doi: 10.1136/jnnp.71.1.40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.71.1.40</ArticleId>
            <ArticleId IdType="pmc">PMC1737458</ArticleId>
            <ArticleId IdType="pubmed">11413260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan HZ, et al.  Limbic Encephalitis Associated with Anti-gamma-aminobutyric Acid B Receptor Antibodies: A Case Series from China. Chinese medical journal. 2015;128:3023–3028. doi: 10.4103/0366-6999.168989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0366-6999.168989</ArticleId>
            <ArticleId IdType="pmc">PMC4795264</ArticleId>
            <ArticleId IdType="pubmed">26608981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet. 1993;341:21–22. doi: 10.1016/0140-6736(93)92485-C.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0140-6736(93)92485-C</ArticleId>
            <ArticleId IdType="pubmed">8093269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, et al.  Recommended diagnostic criteria for paraneoplastic neurological syndromes. Journal of neurology, neurosurgery, and psychiatry. 2004;75:1135–1140. doi: 10.1136/jnnp.2003.034447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2003.034447</ArticleId>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260–271. doi: 10.1378/chest.08-0978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.08-0978</ArticleId>
            <ArticleId IdType="pubmed">19584208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groome PA, et al.  The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2007;2:694–705. doi: 10.1097/JTO.0b013e31812d05d5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JTO.0b013e31812d05d5</ArticleId>
            <ArticleId IdType="pubmed">17762335</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29717222</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>May</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic limbic encephalitis associated with lung cancer.</ArticleTitle>
        <Pagination>
          <StartPage>6792</StartPage>
          <MedlinePgn>6792</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">6792</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-018-25294-y</ELocationID>
        <Abstract>
          <AbstractText>Paraneoplastic limbic encephalitis (PLE) is a rare autoimmune neurological syndrome observed in lung cancer patients. We retrospectively investigated the clinical characteristics, treatment responses, and prognoses in 16 PLE patients who were subsequently diagnosed with lung cancer. Fifteen patients initially presented with disturbance of consciousness, 13 with disorientation, and 12 with seizures. Thirteen patients had autoantibodies, including eight with gamma aminobutyric acid B receptor (GABA<sub>B</sub>R) antibodies and eight with Hu antibodies. PET-CT revealed lung neoplasms in 13 patients, nine of whom exhibited abnormal metabolic activity in the temporal lobe and hippocampus. Fifteen cases were confirmed as limited-stage small cell lung cancer and one as stage IV large cell neuroendocrine carcinoma. Eleven patients received immunomodulatory therapy, and four showed neurological improvement, who all had antibodies against GABA<sub>B</sub>R. Fifteen patients received chemotherapy, of which 14 maintained or improved their PLE status. The overall cancer response rate was 75%, and two-year overall survival was 74.7%. Our results suggest patients with GABA<sub>B</sub> encephalitis might respond better to immunotherapy than the classical PLE patients with anti-Hu antibodies. Anti-cancer treatment could further improve neurological symptoms. Lung cancer patients with PLE, especially those in limited stage, might have better outcome due to earlier diagnosis and prompt anti-cancer treatment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Kaini</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guan</LastName>
            <ForeName>Hongzhi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Minjiang</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Longyun</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Mengzhao</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China. mengzhaowang@sina.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>05</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051959">ELAV Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018080">Receptors, GABA-B</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003221" MajorTopicYN="N">Confusion</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051959" MajorTopicYN="N">ELAV Proteins</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020363" MajorTopicYN="N">Limbic Encephalitis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018080" MajorTopicYN="N">Receptors, GABA-B</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055752" MajorTopicYN="N">Small Cell Lung Carcinoma</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29717222</ArticleId>
        <ArticleId IdType="pmc">PMC5931551</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-018-25294-y</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-018-25294-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Gultekin SH, et al.  Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain: a journal of neurology. 2000;123(Pt 7):1481–1494. doi: 10.1093/brain/123.7.1481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/123.7.1481</ArticleId>
            <ArticleId IdType="pubmed">10869059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, et al.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain: a journal of neurology. 2001;124:1138–1148. doi: 10.1093/brain/124.6.1138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/124.6.1138</ArticleId>
            <ArticleId IdType="pubmed">11353730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheid R, et al.  Neuropsychiatric findings in anti-Ma2-positive paraneoplastic limbic encephalitis. Neurology. 2003;61:1159–1161. doi: 10.1212/01.WNL.0000085873.45099.E2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000085873.45099.E2</ArticleId>
            <ArticleId IdType="pubmed">14581698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gozzard P, et al.  Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study. Neurology. 2015;85:235–239. doi: 10.1212/WNL.0000000000001721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000001721</ArticleId>
            <ArticleId IdType="pmc">PMC4516293</ArticleId>
            <ArticleId IdType="pubmed">26109714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. Journal of neurology. 2010;257:509–517. doi: 10.1007/s00415-009-5431-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-009-5431-9</ArticleId>
            <ArticleId IdType="pubmed">20035430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grisold W, Giometto B, Vitaliani R, Oberndorfer S. Current approaches to the treatment of paraneoplastic encephalitis. Therapeutic advances in neurological disorders. 2011;4:237–248. doi: 10.1177/1756285611405395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756285611405395</ArticleId>
            <ArticleId IdType="pmc">PMC3131173</ArticleId>
            <ArticleId IdType="pubmed">21765874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoftberger R, et al.  Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology. 2013;81:1500–1506. doi: 10.1212/WNL.0b013e3182a9585f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182a9585f</ArticleId>
            <ArticleId IdType="pmc">PMC3888170</ArticleId>
            <ArticleId IdType="pubmed">24068784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelley BP, et al.  Autoimmune Encephalitis: Pathophysiology and Imaging Review of an Overlooked Diagnosis. AJNR Am J Neuroradiol. 2017;38:1070–1078. doi: 10.3174/ajnr.A5086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3174/ajnr.A5086</ArticleId>
            <ArticleId IdType="pubmed">28183838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams TJ, et al.  Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. JAMA neurology. 2016;73:928–933. doi: 10.1001/jamaneurol.2016.1399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2016.1399</ArticleId>
            <ArticleId IdType="pubmed">27271951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fellner, A. et al. Neurologic complications of immune checkpoint inhibitors. Journal of neuro-oncology, 10.1007/s11060-018-2752-5 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29332184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. The Lancet. Neurology. 2002;1:294–305. doi: 10.1016/S1474-4422(02)00135-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(02)00135-7</ArticleId>
            <ArticleId IdType="pubmed">12849427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, et al.  A clinical approach to diagnosis of autoimmune encephalitis. The Lancet. Neurology. 2016;15:391–404. doi: 10.1016/S1474-4422(15)00401-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(15)00401-9</ArticleId>
            <ArticleId IdType="pmc">PMC5066574</ArticleId>
            <ArticleId IdType="pubmed">26906964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serafini A, et al.  Paraneoplastic epilepsy. Epilepsy Behav. 2016;61:51–58. doi: 10.1016/j.yebeh.2016.04.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yebeh.2016.04.046</ArticleId>
            <ArticleId IdType="pubmed">27304613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim TJ, et al.  Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis. Journal of neuroimmunology. 2014;270:45–50. doi: 10.1016/j.jneuroim.2014.02.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2014.02.011</ArticleId>
            <ArticleId IdType="pubmed">24662003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao S, et al.  Clinical Characteristics and Predictors of Outcome for Onconeural Antibody-Associated Disorders: A Retrospective Analysis. Front Neurol. 2017;8:584. doi: 10.3389/fneur.2017.00584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2017.00584</ArticleId>
            <ArticleId IdType="pmc">PMC5694024</ArticleId>
            <ArticleId IdType="pubmed">29180979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ulrich D, Bettler B. GABA(B) receptors: synaptic functions and mechanisms of diversity. Curr Opin Neurobiol. 2007;17:298–303. doi: 10.1016/j.conb.2007.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.conb.2007.04.001</ArticleId>
            <ArticleId IdType="pubmed">17433877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster E, et al.  Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. The Lancet. Neurology. 2010;9:67–76. doi: 10.1016/S1474-4422(09)70324-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(09)70324-2</ArticleId>
            <ArticleId IdType="pmc">PMC2824142</ArticleId>
            <ArticleId IdType="pubmed">19962348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. 2011;76:795–800. doi: 10.1212/WNL.0b013e31820e7b8d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e31820e7b8d</ArticleId>
            <ArticleId IdType="pmc">PMC3053332</ArticleId>
            <ArticleId IdType="pubmed">21357831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: a systematic review. Expert review of neurotherapeutics. 2015;15:1391–1419. doi: 10.1586/14737175.2015.1115720.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14737175.2015.1115720</ArticleId>
            <ArticleId IdType="pubmed">26559389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stinchcombe, T. E. Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer. The oncologist, 10.1634/theoncologist.2017-0204 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5728020</ArticleId>
            <ArticleId IdType="pubmed">28778960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glatzer, M. et al. Treatment of limited disease small cell lung cancer: the multidisciplinary team. The European respiratory journal50, 10.1183/13993003.00422-2017 (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>Kaira K, et al.  Small-cell lung cancer with voltage-gated calcium channel antibody-positive paraneoplastic limbic encephalitis: a case report. Journal of medical case reports. 2014;8:119. doi: 10.1186/1752-1947-8-119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1752-1947-8-119</ArticleId>
            <ArticleId IdType="pmc">PMC4000153</ArticleId>
            <ArticleId IdType="pubmed">24712889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuliani L, et al.  Paraneoplastic limbic encephalitis associated with potassium channel antibodies: value of anti-glial nuclear antibodies in identifying the tumour. Journal of neurology, neurosurgery, and psychiatry. 2007;78:204–205. doi: 10.1136/jnnp.2006.102467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2006.102467</ArticleId>
            <ArticleId IdType="pmc">PMC2077643</ArticleId>
            <ArticleId IdType="pubmed">17229755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bak TH, Antoun N, Balan KK, Hodges JR. Memory lost, memory regained: neuropsychological findings and neuroimaging in two cases of paraneoplastic limbic encephalitis with radically different outcomes. Journal of neurology, neurosurgery, and psychiatry. 2001;71:40–47. doi: 10.1136/jnnp.71.1.40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.71.1.40</ArticleId>
            <ArticleId IdType="pmc">PMC1737458</ArticleId>
            <ArticleId IdType="pubmed">11413260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan HZ, et al.  Limbic Encephalitis Associated with Anti-gamma-aminobutyric Acid B Receptor Antibodies: A Case Series from China. Chinese medical journal. 2015;128:3023–3028. doi: 10.4103/0366-6999.168989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0366-6999.168989</ArticleId>
            <ArticleId IdType="pmc">PMC4795264</ArticleId>
            <ArticleId IdType="pubmed">26608981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet. 1993;341:21–22. doi: 10.1016/0140-6736(93)92485-C.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0140-6736(93)92485-C</ArticleId>
            <ArticleId IdType="pubmed">8093269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, et al.  Recommended diagnostic criteria for paraneoplastic neurological syndromes. Journal of neurology, neurosurgery, and psychiatry. 2004;75:1135–1140. doi: 10.1136/jnnp.2003.034447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2003.034447</ArticleId>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260–271. doi: 10.1378/chest.08-0978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.08-0978</ArticleId>
            <ArticleId IdType="pubmed">19584208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groome PA, et al.  The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2007;2:694–705. doi: 10.1097/JTO.0b013e31812d05d5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JTO.0b013e31812d05d5</ArticleId>
            <ArticleId IdType="pubmed">17762335</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
